CME: Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Directed Therapies Medical Education on ReachMD

Overview
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Target Audience
This activity has been designed to meet the educational needs of the interprofessional team, which includes medical oncologists and oncology nurses, as well as other healthcare providers involved in managing patients with gastric/gastroesophageal junction cancers.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Describe relevant molecular biomarkers and how they relate to clinical characteristics of G/GEJ cancers
- Discuss the impact molecular biomarkers have on treatment selection in metastatic G/GEJ cancers
- Evaluate clinical data with current and investigational combination regimens for the first-line treatment of advanced G/GEJ cancers
- Identify adverse effects associated with individual components of combination regimens and their prophylactic and management strategies in the setting of advanced or metastatic G/GEJ cancers
- Implement strategies to provide holistic, multidisciplinary care for patients with advanced or metastatic G/GEJ cancers
- Evaluate recent practice-changing data to inform treatment strategies for patients with G/GEJ cancers
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
Disclosure of Relevant Financial Relationships
Disclosure Policy
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.

The following faculty have disclosed:
Samuel J. Klempner, MD, faculty for this educational event, is a contracted researcher for AACR, Stand-Up-2-Cancer, NCI, and AGA; and receives consulting fees from Astellas, Merck, Amgen, BMS, AstraZeneca, Merana, Servier, Sanofi-Aventis, Novartis, and Pfizer.
Yelena Y. Janjigian, MD, faculty for this educational event, is a contracted researcher for AstraZeneca, Arcus Biosciences, Bayer, Bristol Myers Squibb, Cycle for Survival, Department of Defense, Eli Lilly, Fred’s Team, Genentech/Roche Inspirna, Merck, NCI, and Transcenta; holds stock options for Inspirna; and receives consulting fees from AbbVie, Amerisource Bergen, Ask-Gene Pharma Inc., Arcus Biosciences, Astellas, AstraZeneca, Basilea Pharmaceutica, Bayer, Bristol-Myers Squibb, Clinical Care Options, Daiichi-Sankyo, Eli Lilly, Geneos Therapeutics, GlaxoSmithKline, Guardant Health, Inc., HMP Education, Imedex, Imugene, Inspirna, Lynx Health, Merck, Merck Serono, Mersana Therapeutics, Michael J. Hennessy Associates, Paradigm Medical Communications, PeerView Institute, Pfizer, Research to Practice, Seagen, Silverback Therapeutics, and Zymeworks Inc.
Planners and Managers Disclosure List
The following planners/reviewers/managers have disclosed:

Megan Reimann, PharmD, BCOP, planner for this educational event, has no relevant financial relationships with ineligible companies.

William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

Total CME, LLC., planners, and managers have no relevant commercial relationships to disclose.

All the relevant financial relationships for these individuals have been mitigated.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use their clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Provider(s)/Educational Partner(s)
Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.
Commercial Support
This activity is supported by independent educational grants from Astellas Pharma Global Development, Inc., and Merck Sharp & Dohme LLC.
Instructions for Completion
During the period 2/5/2024 through 6/19/2025, registered participants wishing to receive continuing education credit for this activity must follow these steps:
1. Read the learning objectives and faculty disclosures.
2. Answer a pre-program question.
3. View the program.
4. Complete the post-test with a score of 100%.
5. Complete activity evaluation.
6. Apply for credit and either bank your credits or print your certificate.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 02/05/2024
Expiration Date: Ongoing Program - Expiration date will be posted when all episodes are published.